AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Jul 6, 2024 - 04:00

AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Read the original article

Tags:

Previous Article

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Enveric’s EB-003 selected as lead candidate for mental health disorders

Enveric’s EB-003 selected as lead candidate for mental ...

Dec 30, 2023

Why the Importer of Record (IoR) is vital in the clinical supply chain

Why the Importer of Record (IoR) is vital in the clinic...

Sep 4, 2024

Pfizer gets grant for treatment of cancer using enginee...

Apr 25, 2024